Wedbush Maintains Rating for Larimar Therapeutics

Summary

Wedbush maintained its rating for Larimar Therapeutics, adjusting the target price from $17.00 to $15.00. Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its main candidate being CTI-1601 aimed at delivering frataxin (FXN) protein.

Impact Analysis

This event is classified at the company level, as it pertains specifically to Larimar Therapeutics. The direct impact of Wedbush’s adjustment in the target price from $17.00 to $15.00 indicates a slightly less optimistic view on the company’s stock valuation. This adjustment reflects potential challenges or reassessments in the company’s developmental pipeline or market conditions. Investors might see this as a signal to reevaluate their positions. However, the average analyst rating for Larimar Therapeutics remains a ‘buy’ with a target price of $20.73, according to FactSet,Trading View suggesting that there is still a positive consensus among analysts despite Wedbush’s adjustment. Other analysts have varied target prices, ranging from $10.00 to $26.00, reflecting differing opinions on the company’s prospects and risks.Market Beat For investors, this highlights the importance of considering a range of analyst opinions and conducting their due diligence before making investment decisions in Larimar Therapeutics.